Intensity Therapeutics Shares Double After Positive Data From Breast-Cancer Treatment Trial

By Chris Wack Intensity Therapeutics shares doubled to $9.09 after the company said it saw positive data from its Phase 2 trial of INT230-6 in patients with...

Related Keywords

,Chris Wack ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Cancer Drugs ,Healthcare Life Sciences ,Biopharmaceuticals ,Specialized Drugs Medications ,Research Development ,Corporate Industrial News ,Breast Cancer ,Cancer ,Political General News ,Chemotherapy Radiotherapy Immunotherapy ,Demographic Health ,Health ,Medical Conditions ,Medical Treatments Procedures ,Women Amp 39s Health ,Synd ,Intensity Therapeutics ,Hints ,Us45828j1034 ,Research ,Development ,Corporate ,Industrial News ,Political ,General News ,Chemotherapy ,Radiotherapy ,Immunotherapy ,Medical Treatments ,Procedures ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,